Healthcare
Live Price
Offline$58.00
-3.33% today
1Y Change
-8.31%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) is a Healthcare stock with a market cap of $10.14B and listed on OTC. The stock last traded around $58.00 and down 8.3% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of +11.8%, EPS growth of +6.4%, a dividend yield of 2.6%. What stands out right now is revenue +11.8%, EPS +6.4%, free cash flow +282.0% with operating margin 27.5% and ROIC 12.1%. The dividend matters to the case here, with a current yield around 2.6%. Valuation is more restrained than many high-expectation growth names at P/E 23.0 and price/sales 3.9. Stock Foundry combines RCDTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RCDTF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RCDTF Max Drawdown
-14.61%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RCDTF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.6B
-14.7% YoY
FY Net Income
$386.0M
+23.6% YoY
Free Cash Flow
$404.3M
+10.7% YoY
Revenue Growth
+11.8%
EPS Growth
+6.4%
Gross Margin
68.3%
Net Margin
16.9%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.6B | 2.3B | 2.1B | 1.9B | 1.6B |
| Gross Profit | 1.8B | 1.6B | 1.5B | 1.3B | 1.2B |
| Operating Income | 720M | 639M | 558M | 437M | 490M |
| EBITDA | 887M | 796M | 709M | 559M | 578M |
| Net Income | 444M | 417M | 389M | 312M | 386M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 429M | 322M | 222M | 285M | 245M |
| Total Assets | 5.3B | 5.1B | 4.2B | 4.0B | 2.8B |
| Total Liabilities | 3.3B | 3.3B | 2.5B | 2.5B | 1.4B |
| Shareholder Equity | 1.9B | 1.9B | 1.7B | 1.5B | 1.4B |
| Total Debt | 24M | 23M | 100M | 1.7B | 992M |
| Net Debt | -405M | -300M | -122M | 1.4B | 748M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
492M
+6.5% YoY
Capital Expenditures
87M
+9.3% YoY
Free Cash Flow
404M
+10.7% YoY
Key ratios
Gross Margin
68.3%
Operating Margin
27.5%
Net Margin
16.9%
ROE
23.1%
Debt / Equity
1.29x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.